DBV Technologies Eyes BLA Submission After $288M Funding, Positive Phase 3 Results
DBV Technologies ended 2025 with $194 million in cash and cash equivalents plus $94 million of gross proceeds, securing funding into Q2 2027. The company reported positive Phase 3 VITESSE topline results in peanut-allergic children, initiated the COMFORT Toddlers safety study and plans BLA submission for ages 4–7 in H1 2026.
1. Financial Position and Funding
DBV held $194 million in cash and cash equivalents at December 31, 2025 and received an additional $94 million of gross proceeds on January 16, 2026 from private placements and ATM subscriptions, securing operating runway into the second quarter of 2027.
2. Clinical Development Highlights
DBV reported positive topline results from its Phase 3 VITESSE trial in peanut-allergic children aged 4 to 7 years and initiated the COMFORT Toddlers safety study in children aged 1 to 3 years, while planning a supplemental trial assessing VIASKIN® Peanut Patch efficacy in infants aged 6 to 12 months.
3. Leadership and Regulatory Outlook
DBV strengthened its executive team by appointing a Chief Commercial Officer and Chief Human Resources Officer and added a biotechnology strategy expert to its Board of Directors. The company expects to submit a Biologics License Application for the 4–7 age group in the first half of 2026 and pursue accelerated approval for ages 1–3 in the second half of 2026.